AVBCC 2015 5th Annual Conference Abstracts

Washington, DC—Complex partnerships among cancer care stakeholders, including drug manufacturers, are becoming the norm.
  • 4-Year Employer Trends and Value-Based Oncology Coverage–Related Findings from a National Employer Survey
  • Willingness to Pay for Treatment Among Women with Metastatic Breast Cancer
  • Current Practices in the Use of Next-Generation Sequencing: A Steep Learning Curve?
  • Using Data to Improve Quality of Care and Process Sheryl Riley
  • Treatment-Sequencing Patterns of Novel Agents in Patients with Prostate Cancer
  • Prostate Cancer Assay Improves Treatment Decisions for Patients with Early-Stage Disease
  • Defining Value in Oncology: Perspectives from Patients with Metastatic Breast Cancer
  • Examining Experiences of Patients Currently Being Treated with Abiraterone Acetate for Metastatic Castrate-Resistant...
  • Myeloid Growth Factor Utilization in a Commercial and Medicare Population: Phase 1 of a Quality Improvement Initiative
  • Improving the Awareness, Identification, and Management of Sarcopenic Obesity: An Evidence-Based Toolbox
  • Measuring the Value of Telephone Distress Screening and Referral on Resource Utilization and Distress in Patients with...
  • Demonstrating Return on Investment for Stakeholders in a Care Coordination Program
  • Budget Impact Analysis of Abiraterone Acetate plus Prednisone versus Enzalutamide for the Treatment of Patients with...
  • Budget Impact Analysis of Ibrutinib for Patients with Previously Treated Mantle-Cell Lymphoma
  • Cost-Effectiveness of Octreotide LAR versus Lanreotide Depot in the Treatment of Metastatic Gastrointestinal...
  • Patterns of Utilization of Bortezomib Retreatment in Patients with Relapsed and/or Refractory Multiple Myeloma Who...
  • Utilization Beyond Traditional Oncology Care Management: Utilizing Multiple Data Sets and Clinical Tools to Improve the...
  • Utilization of the New Agents Carfilzomib and Pomalidomide in Relapsed and/or Refractory Multiple Myeloma: Analysis...
  • Economic Impact of a Novel Circulating Tumor DNA Test for Third-Generation EGFR TKI Biomarker Testing in NSCLC

Results 1 - 2 of 2
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology